Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema

NCT: NCT02506530 · COMPLETED

NCT IDNCT02506530
StatusCOMPLETED
Start Date2015-09
Completion2018-12
SponsorUniversity Hospital, Toulouse (OTHER)
First posted
Last updated

Brief Summary

This study will assess the benefit of LPG Cellu M6 in addition of intensive decongestive treatment in reducing secondary lymphoedema in breast cancer.

Frequently Asked Questions

What is Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema?

Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema is a clinical trial registered under NCT02506530. Current status: COMPLETED.

What is the status of NCT02506530?

The current status of NCT02506530 (Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema) is: COMPLETED.

When did Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema start?

Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema started on 2015-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑